J&J director says company could boost vaccine availability by spring, CNBC says » 16:1801/2201/22/21
Johnson & Johnson…
Johnson & Johnson board member Dr. Mark McClellan said that "if the clinical trial works out," the company may be able to significantly boost America's COVID-19 vaccine supply availability within a matter of weeks, CNBC's Emily DeCiccio reports. I do know that J&J is making a very large supply, going all out with its production, both here in the U.S. and elsewhere around the world, with the goal of having perhaps enough vaccines for 100 million Americans by spring, by this April or so," said the former FDA Commissioner in a Thursday evening interview on CNBC. Reference Link
Intuitive Surgical price target raised to $840 from $825 at JPMorgan » 09:5501/2201/22/21
JPMorgan analyst Tycho…
JPMorgan analyst Tycho Peterson raised the firm's price target on Intuitive Surgical to $840 from $825 and reiterates an Overweight rating on the shares following last night's "solid" results. The quarter showcased a "measured recovery," and the rollout of flexible financing programs, combined with disciplined investments, are "smart moves to grow the competitive moat ahead of new entrants," Peterson tells investors in a research note. The analyst continues to see longer-term catalysts to drive upside, including the China quota, unpenetrated procedures, SP ramp and Ion commercial ramp.
Intuitive Surgical price target raised to $865 from $800 at Raymond James » 09:2001/2201/22/21
Raymond James analyst…
Raymond James analyst Lawrence Keusch raised the firm's price target on Intuitive Surgical to $865 from $800 and keeps an Outperform rating on the shares following the company's "solid" Q4 results. Looking into 2021, Keusch says there remains COVID-related uncertainty and he expects Q1 to be the most significantly impacted period of the year.
Intuitive Surgical price target raised to $879 from $841 at Wells Fargo » 07:0201/2201/22/21
Wells Fargo analyst…
Wells Fargo analyst Lawrence Biegelsen raised the firm's price target on Intuitive Surgical to $879 from $841 and keeps an Overweight rating on the shares. The company's Q4 results were driven by better-than-expected da Vinci shipments and higher stocking orders as a result of the Extended Use program, Biegelsen tells investors in a research note.
Intuitive Surgical price target raised to $410 from $365 at Oppenheimer » 06:2901/2201/22/21
Oppenheimer analyst Suraj…
Oppenheimer analyst Suraj Kalia raised the firm's price target on Intuitive Surgical to $410 from $365 and keeps an Underperform rating on the shares following its Q4 earnings report. Kalia believes the fundamentals remain challenged despite a valuation that seems overly optimistic.
Intuitive Surgical price target raised to $730 from $680 at Piper Sandler » 05:0201/2201/22/21
Piper Sandler analyst…
Piper Sandler analyst Adam Maeder raised the firm's price target on Intuitive Surgical to $730 from $680 and keeps a Neutral rating on the shares following the company's "solid" Q4 results. model. There were no real surprises on the earnings call given the pre-announcement and the company elected not to provide any financial guidance due to the ongoing pandemic, Maeder tells investors in a research note.
Fly Intel: After-Hours Movers » 18:3501/2101/21/21
SIVB, WAL, INDB, OZK, FLDM, MNOV, SWIR, ALDX, AMRN, IBM, STX, PPG, ISRG, CSX, PGEN, ACB, F
Check out this evening's…
Intuitive Surgical says overall procedure growth was 6% in Q4 » 17:0101/2101/21/21
Says delays in diagnostic…
Says delays in diagnostic pipelines due to COVID-19 will likely take quarters to resolve. Says delays will also pressure new system installs. Says obstacles make predictions for next couple of quarters difficult. Says resurgence of Covid in parts of Europe had a large impact on procedures. Says resurgence also impacted U.S. market. Says half of the systems placed in Q4 involved trade-ins. Says Q4 average selling prices decreased. Says procedure growth accelerated in China. Comments taken from Q4 earnings conference call.
ViiV Healthcare announces FDA approval of Cabenuva » 16:4601/2101/21/21
GSK, PFE, JNJ
ViiV Healthcare, the…
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced that the U.S. FDA approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines, ViiV Healthcare's cabotegravir and Janssen's (JNJ) rilpivirine, dosed once monthly, as an option to replace the current antiretroviral regimen in those who are virologically suppressed on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.
Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 » 16:0901/2101/21/21
Reports Q4 revenue…
Reports Q4 revenue $1.33B, consensus $1.24B. Worldwide da Vinci procedures increased approximately 6% compared with Q4 of 2019, reflecting continued disruption caused by the COVID-19 pandemic. The company shipped 326 da Vinci Surgical Systems, a decrease of 3% compared with 336 in Q4 of 2019. The company said, "During 2020, da Vinci procedure volumes and system placements were significantly impacted by the COVID-19 pandemic, as healthcare systems around the world diverted resources to respond to COVID-19. The impact of the COVID-19 pandemic on the Company's business has, and continues to, differ by geography and region. In the U.S., for example, while da Vinci procedures had recovered a significant portion of the pre-COVID-19 levels, the resurgence of COVID-19, particularly later in the fourth quarter and into January, has had, and will likely continue to have, an adverse impact on the Company's procedure volumes. Due to the continued uncertainty around the scope and duration of the pandemic globally, we cannot, at this time, reliably estimate the future impact on our operations and financial results."